Saxagliptin Market to Exhibit Impressive Growth by 2020
Diabetes is the chronic condition associated with the abnormally high level of glucose in the blood. Insufficient or nonproduction of insulin in pancreas causes diabetes. Globally, the incidence of diabetes is increasing significantly and it is becoming a significant burden. According to the World Health Organization (WHO), approximately 221 million people are suffering from diabetes. There are large numbers of blood glucose-lowering drugs. Saxagliptin is an oral anti-diabetic agent known as DPP IV inhibitor. DDP IV inhibitor is an enzyme...
View full press release